Stock BVNRY BAVARIAN NORDIC A/S
Add to a list
To use this feature you must be a member
Log inSign up

News Bavarian Nordic A/S OTC Markets

Equities

BVNRY

US0717711099

Market Closed - OTC Markets
Other stock markets
 15:56:03 2024-05-31 EDT 		5-day change 1st Jan Change
8.93 USD +4.66% Intraday chart for Bavarian Nordic A/S +3.18% +2.12%
05-31 Bavarian Nordic Files for Supplemental US License for Smallpox-Monkeypox Vaccine MT
05-30 Bavarian Nordic Gets $6.5 Million Funding for Development of Mpox Vaccine in Children MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Bavarian Nordic Files for Supplemental US License for Smallpox-Monkeypox Vaccine
MT
Bavarian Nordic Submits Supplemental BLA Seeking U.S. FDA Approval of Freeze-Dried Formulation of Smallpox and Mpox Vaccine
GL
Bavarian Nordic Gets $6.5 Million Funding for Development of Mpox Vaccine in Children
MT
Bavarian Nordic and CEPI Partners to Advance Mpox Vaccination in Africa
GL
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
GL
Bavarian Nordic A/S : Transactions in Connection with Share Buy Back Program and Termination of Share Buy Back Program
PU
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back Program
GL
Bavarian Nordic’s Medical Chief to Step Down by May-end
MT
EVP and Chief Medical Officer Laurence de Moerlooze Will Be Leaving Bavarian Nordic
GL
Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer
CI
Transcript : Bavarian Nordic A/S, Q1 2024 Earnings Call, May 08, 2024
Bavarian Nordic Launches Share Buy-Back Program to Hedge Incentive Scheme Obligations
GL
Bavarian Nordic A/S commences an Equity Buyback Plan, under the authorization approved on April 16, 2024.
CI
Bavarian Nordic A/S : Interim Results (Q1) as of 31 March 2024
PU
Bavarian Nordic Announces Interim Results for the First Three Months of 2024
GL
Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024
CI
Bavarian Nordic A/S Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
GL
Bavarian Nordic Books EUR65 Million Order for Smallpox Vaccine
MT
Bavarian Nordic Receives 65 mEUR Contract to Supply Smallpox Vaccines for EU Strategic Reserve
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BAVA Stock
  4. BVNRY Stock
  5. News Bavarian Nordic A/S